1 Min Read
Feb 5 (Reuters) - Fibrocell Science Inc:
* FIBROCELL SCIENCE SAYS EXPECT TO INITIATE A SAFETY CLINICAL TRIAL IN 2018 FOR FCX-013 DEVELOPMENT - SEC FILING Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.